INTRODUCTION
Antiestrogenic therapy, performed either by tamoxifen-mediated estrogen receptor inhibition or by estrogen deprivation through aromatase inhibitors (AIs), is an effective treatment for patients with hormone receptor-positive breast cancer. 1, 2 In recent years, it has become evident that up-front AIs for 5 years and sequential therapy with tamoxifen for 2 to 3 years followed by AIs provide more benefit than 5 years of tamoxifen alone, at least in the postmenopausal situation. [3] [4] [5] [6] In premenopausal women, the role of AIs is less clear. 7 Although they cannot be used alone in young patients because of ovarian hyperstimulation, it is in principle attractive to combine them with luteinizing hormone-releasing hormone agonists to improve on established tamoxifen-based treatment. 8, 9 Several prospective clinical trials are investigating the role of AIs in premenopausal patients with breast cancer. 10, 11 Early results of one of these trials (Austrian Breast and Colorectal Cancer Study Group [ABCSG] 12) indicate that in combination with goserelin, AIs are, in general, an effective endocrine treatment in the premenopausal situation but not superior compared with tamoxifen. 11 Generally, in contrast to tamoxifen, the clinical decision of whether to use an AI as endocrine treatment is not dependent on the abundance or expression of its target (ie, aromatase) but on the expression of hormone receptors, which depict an indirect target. 12, 13 It is currently unknown whether patients with suppressed ovarian function, who have a high abundance of aromatase and therefore
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high estrogen serum levels, derive the same benefit from AIs as patients with a low abundance of this enzyme and therefore low estrogen serum levels. However, not only is measurement of aromatase impracticable for the daily clinical routine, but there is also a matter of debate about where to measure it (eg, in breast tissue, subcutaneous fat tissue, visceral fat tissue, or all of these tissues). It is widely accepted that serum estradiol levels of postmenopausal women do correlate with body mass index (BMI).
14 This correlation is mainly based on increased total-body aromatization of overweight women.
15-17 Therefore, it can be assumed that BMI can serve as a good surrogate parameter and a practicable method to estimate an individual person's total-body aromatization.
We hypothesized that BMI as a surrogate parameter for totalbody aromatization impacts on the efficacy of AIs but not tamoxifen. To test our hypothesis, we analyzed this question in the data set of the prospective ABCSG-12 trial, which compared endocrine treatment of goserelin in combination with tamoxifen versus anastrozole in premenopausal patients with endocrine-responsive breast cancer.
PATIENTS AND METHODS
The ABCSG-12 trial included premenopausal patients with breast cancer who had been randomly assigned 1:1:1:1 to receive goserelin (3.6 mg subcutaneously every 28 days) plus tamoxifen (20 mg/d orally) or anastrozole (1 mg/d orally) with or without zoledronic acid (initially 8 mg intravenously every 4 weeks; then after 254 patients were enrolled, 4 mg intravenously every 6 months) for 3 years (Fig 1) .. All patients in this trial were hormone receptor positive as defined by the expression of estrogen receptor (ER) and/or progesterone receptor (PR). Patients with a tumor stage IB, IC, or II irrespective of nodal stage (Ͻ 10 positive nodes) were included. Although less than 6% of the patients had been treated with neoadjuvant chemotherapy, none had received adjuvant chemotherapy. The primary end point was disease-free survival (DFS), which was defined as the time from random assignment to the first occurrence of locoregional recurrence, distant metastasis, cancer in the contralateral breast, second primary cancer, or death from any cause. Secondary end points were recurrence-free survival, overall survival (OS), and measures of bone mineral density. Details of the protocol have been reported elsewhere. 11 The trial was done in accordance with the Declaration of Helsinki and under the principles of good clinical practice. This study has been approved by regulatory and ethics committees for all participating centers. Written informed consent was signed by all participating patients.
For this analysis, patients with a BMI ranging from 18.5 to 24.9 kg/m 2 were considered to be normal weight, patients with a BMI ranging from 25 to 29.9 kg/m 2 were overweight, and patients with a BMI of Ն 30 kg/m 2 were obese, according to the WHO criteria. Weight and height were taken at baseline for calculation of BMI. Patients without information on height, weight, or both and underweight patients (BMI Ͻ 18.5 kg/m 2 ) were excluded from the analyses.
The data were retrospectively analyzed for DFS and OS according to the BMI subgroups as well as two treatment arms (tamoxifen v anastrozole). Groups were compared using a Cox proportional hazards regression model, and the log-rank test was used for DFS and OS. Kaplan-Meier plots for DFS and OS were used for each comparison. Each Cox model was adjusted for the effects of zoledronic acid. A multivariate Cox regression model with adjustment for tumor stage, nodal stage, grade, ER, PR, and age was performed for the comparison of overweight versus normal weight patients treated with anastrozole and for the comparison of overweight patients treated with anastrozole versus tamoxifen. The Fisher's exact test and Kruskal-Wallis test were used for comparison of demographic data. Comparison of adverse events between treatment regimens stratified by BMI categories was done using the Cochran-Mantel-Haenszel test. All P values are two sided, and P Ͻ .05 was considered statistically significant.
RESULTS
The ABCSG-12 trial enrolled 1,803 premenopausal women with early breast cancer. Complete patient information was available for 1,736 patients (96%). Because the underweight population (22 patients [2.4%] in the tamoxifen arm and 30 patients [3.3%] in the anastrozole arm) was excluded because of small numbers and biologic reasons, a total of 1,684 premenopausal patients with breast cancer were included in these analyses. Two thirds of these patients were normal weight (n ϭ 1,111), and one third were overweight (n ϭ 391) or obese (n ϭ 182). Demographics and clinical characteristics of both treatment arms according to BMI (normal weight v overweight) are listed in Table 1 . Treatment groups of normal weight and overweight patients were well balanced with regard to demographic and breast cancer characteristics.
Efficacy: Normal Weight Versus Overweight
The median follow-up time for this analysis was 62.6 months. One hundred seventy-nine events, including 66 deaths, are included in this analysis. All deaths were breast cancer related, except for two deaths that were caused by accidents. Comparing the group of normal weight patients (n ϭ 1,111) with the group of overweight patients (n ϭ 573), a trend for a worse outcome of overweight patients regarding DFS (hazard ratio [HR], 1.24; 95% CI, 0.92 to 1.68; P ϭ .15) and OS (HR, 1.49; 95% CI, 0.92 to 2.43; P ϭ .1) was observed. However, BMI showed no prognostic impact in patients treated with tamoxifen. In this group of patients, DFS (HR, 0.94; 95% CI, 0.60 to 1.64; P ϭ .76) and OS (HR, 0.83; 95% CI, 0.35 to 1.93; P ϭ .65) were not significantly different between normal weight patients and overweight patients (Fig 2) .
In contrast, when treated with anastrozole, overweight patients had a significant increase in the risk of disease recurrence compared with normal weight patients (15.1% v 9%, respectively; P ϭ .02). This absolute increase of 6.1% translates into a 60% relative increase in risk for disease recurrence of overweight patients compared with normal weight patients treated with anastrozole (Fig 2) . Regarding OS, overweight patients treated with anastrozole had more than a doubling in the risk of death compared with normal weight patients who received anastrozole (HR, 2.14; 95% CI, 1.17 to 3.92; P ϭ .01). The impact of BMI on the efficacy of anastrozole was confirmed by a multivariate Cox regression model, which adjusted for tumor stage, nodal stage, grade, ER, PR, and age (DFS: HR, 1.53; 95% CI, 1.01 to 2.31; P ϭ .04; OS: HR, 1.93; 95% CI, 1.04 to 3.58; P ϭ .03).
Efficacy: Anastrozole Versus Tamoxifen
When anastrozole was compared with tamoxifen in the normal weight group of patients, no difference with regard to DFS (HR, 0.87; 95% CI, 0.59 to 1.27; P ϭ .45) or OS (HR, 1.21; 95% CI, 0.63 to 2.33; P ϭ .58) was detected. In contrast, in the overweight patient group, patients treated with anastrozole had a 49% increase in the risk of disease recurrence compared with patients treated with tamoxifen (15.0% v 10.2%, respectively; P ϭ .08; Fig 3) . Overweight patients treated with anastrozole had a three-fold increase in the risk of death compared with overweight patients treated with tamoxifen (HR, 3.03; 95% CI, 1.35 to 6.82; P ϭ .004). Translated into absolute differences, this is a 5.2% increase in the risk of death for overweight patients treated with anastrozole compared with tamoxifen (7.9% v 2.7%, respectively; P ϭ .004).
This predictive impact of BMI was confirmed by a multivariate Cox regression model, which was adjusted for tumor stage, nodal stage, grade, ER, PR, and age (DFS: HR, 1.47; 95% CI, 0.90 to 2.40; P ϭ .12; OS: HR, 3.23; 95% CI, 1.39 to 7.53; P ϭ .007). Events in the normal weight patient group and the overweight patient group each treated with tamoxifen versus anastrozole are listed in Table 2 .
No differences in the events of normal weight patients treated with tamoxifen versus anastrozole could be demonstrated. As mentioned earlier, there were more overall events in overweight patients treated with anastrozole compared with overweight patients treated with tamoxifen. Interestingly, the difference in events in the two groups was mainly a result of nearly a doubling of the distant recurrences of patients treated with anastrozole compared with patients treated with tamoxifen (9.0% v 5.1%, respectively).
Impact of BMI on the Efficacy of Zoledronic Acid
Zoledronic acid compared with placebo improved DFS in normal weight and overweight patients to the same amount. No difference in DFS or OS was observed regarding direct comparison of normal weight versus overweight patients both treated with zoledronic acid (data not shown).
Safety and Tolerability
Anastrozole and tamoxifen were well tolerated in patients with both normal and elevated BMI. No relevant advantages of one treatment arm according to adverse effects could be demonstrated. Patients treated with anastrozole experienced more bone pain and arthralgia compared with patients treated with tamoxifen; this was true for normal weight patients (40.6% v 29.5% and 22.1% v 8.5%, respectively) and overweight patients (40.1% v 26.2% and 20.8% v 8.8%, respectively). However, endometrial hyperplasia and uterine polyps occurred more often in normal weight and overweight patients treated with tamoxifen compared with anastrozole. The adverse effects of both treatments arms according to BMI are listed in Table 3 .
DISCUSSION
The hypothesis that led to these analyses was that the amount of total-body aromatization capacity indicated by BMI may influence the efficacy of AIs to fully block aromatase and thereby influence the effort to maximally lower serum estrogen levels. In postmenopausal women and in premenopausal women with ovarian suppression, the major source of serum estrogens is the fat tissue, in which precursors are metabolized to estrogens by the enzyme aromatase. 18 Thus, an increase in BMI leads to an increase in total-body aromatization and, consequently, an increase in estrogen serum levels, which impact on breast cancer. [15] [16] [17] 19 Taken together, this suggests that BMI may serve as a useful surrogate parameter for total-body aromatization and eventually may be a practicable tool to tailor AI therapy for individual patients.
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In fact, we were able to demonstrate that overweight patients (BMI Ն 25 kg/m 2 ) treated with anastrozole did worse compared with tamoxifen regarding DFS and OS, whereas this was not the case for normal weight patients. It is possible that in overweight patients, anastrozole was not able to suppress estrogen serum levels to the same extent as in normal weight patients, whereas tamoxifen competitively blocked the ER in overweight and normal weight patients. Incomplete estrogen serum level suppression in overweight patients could theoretically be overcome by an increased dose of AIs. Because serial estrogen serum levels are not available from patients in the trial, this conclusion currently remains speculative, but the biologic plausibility is strong. However, incomplete ovarian suppression by goserelin in overweight patients might contribute to our findings. As recently shown by Carlson et al, 20 anastrozole in combination with goserelin was not able to steadily suppress estradiol serum levels to the postmenopausal range in three of 32 patients with metastatic breast cancer, which might be a result of incomplete ovarian suppression. Prospective clinical trials are needed to clarify the contribution of possible incomplete aromatase inhibition and possible incomplete ovarian suppression in overweight premenopausal patients to our results.
Although particularly striking in this patient population, the impact of BMI on breast cancer is not limited to endocrine-responsive tumors. As shown by others, increased BMI leads to impaired DFS and OS in pre-and postmenopausal patients with breast cancer. [21] [22] [23] Therefore, lifestyle interventions resulting in weight loss, in combination with increased physical activity, could improve outcome of overweight patients with breast cancer and should be investigated in clinical trials.
The worse prognosis of overweight patients may be a result of initially larger tumor size (because of delayed detection) and higher nodal stage, which is not true for our collective, or it may be a result of altered endocrine functions of the fat tissue and comorbidities. Hence, various confounding factors might be involved in the worse prognosis of overweight premenopausal patients with breast cancer in our patient collective as well. However, we were not able to demonstrate a prognostic impact of BMI in the group of patients treated with tamoxifen. According to the analysis of the Danish Breast Cancer Cooperative Group on the impact of BMI on breast cancer prognosis, which was presented at the San Antonio Breast Cancer Symposium in 2009, it might be that differences in this group of patients appear after a follow-up of 5 years.
24
The significant and marked prognostic impact of BMI in the group of patients treated with anastrozole may be a result of an incomplete estrogen serum level suppression by AIs and/or incomplete ovarian suppression in overweight women, as discussed earlier, but could additionally be explained by a well-known cross-talk between the estrogen signaling system and the insulin/insulin-like growth factor (IGF) signaling system. [25] [26] [27] [28] [29] Because insulin and IGF serum levels are increased in overweight patients, indirect ER activation by insulin/IGF might contribute, at least in part, to the impact of BMI on the efficacy of anastrozole in our collective.
Regarding the nature of the observed events, the difference between anastrozole versus tamoxifen in the overweight group of our collective was mainly a result of an almost doubling of distant recurrences in patients treated with anastrozole (9% v 5.1%, respectively). The markedly higher rate of distant recurrences may be an explanation for the even more pronounced increase in the risk of death of patients HR 
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www.jco.org treated with anastrozole compared with tamoxifen in the overweight group. However, we cannot completely rule out that there are also additional factors correlated with BMI contributing to increased mortality after recurrence such as a higher frequency of comorbidities. However, because we found no differences in death without prior recurrence, this seems to be unlikely. Our data are supported by data from others. The National Surgical Adjuvant Breast and Bowel Project B14 trial, which compared 5 years of tamoxifen versus placebo in patients with endocrine-responsive, lymph node-negative breast cancer, demonstrated no influence of BMI on the efficacy of tamoxifen in postmenopausal patients. 30 In a subgroup analysis of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, investigators demonstrate that there seems to be no benefit of anastrozole over tamoxifen for postmenopausal patients with breast cancer with a BMI of greater than 26.75 kg/m 2 , which is different from the overall result of the ATAC trial. 31 However, it is not reported why the authors set their BMI cutoff at 26.75 kg/m 2 . In a recently published analysis of the ATAC trial, Sestak et al 32 report that the superiority of anastrozole over tamoxifen seems to be more pronounced in postmenopausal patients with breast cancer with lower BMI levels compared with overweight/obese patients. This leads to the assumption that BMI impacts on the efficacy of AIs similarly in both pre-and postmenopausal patients. The greater impact in the premenopausal situation may be, at least in part, a result of the possible incomplete ovarian suppression by goserelin in overweight women.
Clearly, these results should currently be viewed as hypothesis generating because of the retrospective nature of our analyses. In current clinical practice, however, physicians may want to include this aspect in the risk-benefit assessment in counseling overweight premenopausal patients with breast cancer about their choice of adjuvant endocrine treatment.
In conclusion, our analysis of the ABCSG-12 trial suggests that BMI significantly influences the efficacy of anastrozole plus goserelin in premenopausal patients with endocrine-responsive breast cancer. Overweight premenopausal patients do worse with regard to DFS and OS when treated with anastrozole plus goserelin compared with tamoxifen plus goserelin. Because approximately one third of premenopausal patients with breast cancer are overweight, the impact of BMI may indeed be clinically relevant. 
